Literature DB >> 30076171

Responsiveness of histological disease activity indices in ulcerative colitis: a post hoc analysis using data from the TOUCHSTONE randomised controlled trial.

Vipul Jairath1, Laurent Peyrin-Biroulet2, Guangyong Zou1, Mahmoud Mosli3, Niels Vande Casteele1, Reetesh K Pai4, Mark A Valasek5, Aude Marchal-Bressenot6, Larry W Stitt1, Lisa M Shackelton1, Reena Khanna1, Geert R D'Haens1, William J Sandborn1, Allan Olson7, Brian G Feagan1, Rish K Pai8.   

Abstract

OBJECTIVE: We evaluated the reliability and responsiveness of available but incompletely validated UC histological disease activity indices using standardised rules for centralised assessment.
DESIGN: Disease activity was assessed in biopsies collected in a phase II placebo-controlled ozanimod trial by four blinded pathologists using the Geboes (GS) and modified Riley (MRS) scores, the Robarts Histopathology (RHI) and Nancy Histological (NHI) indices and a Visual Analogue Scale. Reliability was assessed with intraclass correlation coefficients (ICCs). Index responsiveness was evaluated by assessing longitudinal validity (Pearson correlations of changes in index scores and other disease measures), and effect size estimates (standardised effect size (SES)) using two criteria for change (treatment assignment and >2 point decrease in total Mayo Clinic score). Area under the receiver operating characteristic (AUROC) curve estimates evaluated the probability of the indices to discriminate between treatment and placebo.
RESULTS: Inter-rater reliability of the histological indices was substantial to almost perfect (ICC>0.61), and responsiveness was moderate to large (SES estimates>0.5); 0.81 (0.52, 1.10), 0.87 (0.58, 1.17), 0.57 (0.30, 0.84) and 0.81 (0.52, 1.09) when treatment assignment was the criterion for change and 1.05 (0.80, 1.31), 1.13 (0.87, 1.39), 0.88 (0.64, 1.12) and 1.06 (0.80, 1.31) for the change in Mayo score criterion for the GS, MRS, RHI and NHI, respectively. The indices had similar drisciminative ability based on AUROC estimates (range 0.608-0.649).
CONCLUSION: All four existing histological indices were similarly reliable and responsive based on this dataset. © Author(s) (or their employer(s)) 2019. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  histopathology; ulcerative colitis

Mesh:

Substances:

Year:  2018        PMID: 30076171     DOI: 10.1136/gutjnl-2018-316702

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  8 in total

1.  Complete histologic normalisation is associated with reduced risk of relapse among patients with ulcerative colitis in complete endoscopic remission.

Authors:  Kelly C Cushing; William Tan; David H Alpers; Vikram Deshpande; Ashwin N Ananthakrishnan
Journal:  Aliment Pharmacol Ther       Date:  2019-11-07       Impact factor: 8.171

2.  An International Consensus to Standardize Integration of Histopathology in Ulcerative Colitis Clinical Trials.

Authors:  Christopher Ma; Rocio Sedano; Ahmed Almradi; Niels Vande Casteele; Claire E Parker; Leonardo Guizzetti; David F Schaeffer; Robert H Riddell; Reetesh K Pai; Robert Battat; Bruce E Sands; Christophe Rosty; Marla C Dubinsky; Florian Rieder; Noam Harpaz; Maria T Abreu; Robert V Bryant; Gregory Y Lauwers; Richard Kirsch; Mark A Valasek; Eileen Crowley; William J Sandborn; Brian G Feagan; Rish K Pai; Vipul Jairath
Journal:  Gastroenterology       Date:  2021-02-19       Impact factor: 22.682

3.  Can advanced endoscopic techniques for assessment of mucosal inflammation and healing approximate histology in inflammatory bowel disease?

Authors:  Olga Maria Nardone; Rosanna Cannatelli; Davide Zardo; Subrata Ghosh; Marietta Iacucci
Journal:  Therap Adv Gastroenterol       Date:  2019-07-18       Impact factor: 4.409

4.  Validation of the 'Inflammatory Bowel Disease-Distribution, Chronicity, Activity [IBD-DCA] Score' for Ulcerative Colitis and Crohn´s Disease.

Authors:  Corinna Lang-Schwarz; Miriam Angeloni; Abbas Agaimy; Raja Atreya; Christoph Becker; Theresa Dregelies; Silvio Danese; Jean-François Fléjou; Nikolaus Gaßler; Heike I Grabsch; Arndt Hartmann; Kateřina Kamarádová; Anja A Kühl; Gregory Y Lauwers; Alessandro Lugli; Iris Nagtegaal; Markus F Neurath; Georg Oberhuber; Laurent Peyrin-Biroulet; Timo Rath; Robert Riddell; Carlos A Rubio; Kieran Sheahan; Britta Siegmund; Herbert Tilg; Vincenzo Villanacci; Maria Westerhoff; Fulvia Ferrazzi; Michael Vieth
Journal:  J Crohns Colitis       Date:  2021-10-07       Impact factor: 9.071

Review 5.  Histological Scores in Patients with Inflammatory Bowel Diseases: The State of the Art.

Authors:  Edoardo Vespa; Ferdinando D'Amico; Mauro Sollai; Mariangela Allocca; Federica Furfaro; Alessandra Zilli; Arianna Dal Buono; Roberto Gabbiadini; Silvio Danese; Gionata Fiorino
Journal:  J Clin Med       Date:  2022-02-11       Impact factor: 4.241

6.  PICaSSO Histologic Remission Index (PHRI) in ulcerative colitis: development of a novel simplified histological score for monitoring mucosal healing and predicting clinical outcomes and its applicability in an artificial intelligence system.

Authors:  Xianyong Gui; Alina Bazarova; Rocìo Del Amor; Vincenzo Villanacci; Michael Vieth; Gert de Hertogh; Davide Zardo; Tommaso Lorenzo Parigi; Elin Synnøve Røyset; Uday N Shivaji; Melissa Anna Teresa Monica; Giulio Mandelli; Pradeep Bhandari; Silvio Danese; Jose G Ferraz; Bu'Hussain Hayee; Mark Lazarev; Adolfo Parra-Blanco; Luca Pastorelli; Remo Panaccione; Timo Rath; Gian Eugenio Tontini; Ralf Kiesslich; Raf Bisschops; Enrico Grisan; Valery Naranjo; Subrata Ghosh; Marietta Iacucci
Journal:  Gut       Date:  2022-02-16       Impact factor: 23.059

Review 7.  A Literature Review of Ozanimod Therapy in Inflammatory Bowel Disease: From Concept to Practical Application.

Authors:  Noah Becher; Arun Swaminath; Keith Sultan
Journal:  Ther Clin Risk Manag       Date:  2022-09-08       Impact factor: 2.755

Review 8.  Histopathological assessment of the microscopic activity in inflammatory bowel diseases: What are we looking for?

Authors:  Ondrej Fabian; Lukas Bajer
Journal:  World J Gastroenterol       Date:  2022-09-28       Impact factor: 5.374

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.